tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Aspira Women’s Health Expands Reach via Mayo Clinic Partnership

Story Highlights
  • Aspira signed a five-year deal to provide Ova1Plus and OvaWatch tests to Mayo Clinic Laboratories.
  • Mayo will list, order, and bill for Aspira’s tests, potentially broadening Aspira’s diagnostic market reach.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Aspira Women’s Health Expands Reach via Mayo Clinic Partnership

Claim 70% Off TipRanks This Holiday Season

An update from Aspira Women’s Health ( (AWHL) ) is now available.

On December 16, 2025, Aspira Women’s Health entered into a five-year Laboratory Services Agreement with Mayo Collaborative Services, doing business as Mayo Clinic Laboratories, under which Aspira will supply its Ova1Plus and OvaWatch tests to Mayo on a non-exclusive, as-requested basis for clinical use. Mayo will add Aspira’s tests to its catalog, manage ordering, results delivery and billing, while Aspira invoices Mayo at fixed fees during the initial term, a structure that expands Aspira’s clinical reach through Mayo’s network and could strengthen its market position in ovarian cancer risk assessment diagnostics without exclusivity constraints.

The most recent analyst rating on (AWHL) stock is a Sell with a $0.37 price target. To see the full list of analyst forecasts on Aspira Women’s Health stock, see the AWHL Stock Forecast page.

Spark’s Take on AWHL Stock

According to Spark, TipRanks’ AI Analyst, AWHL is a Underperform.

The overall stock score is primarily driven by poor financial performance and valuation metrics, reflecting significant risks due to negative equity and ongoing losses. Technical analysis indicates bearish momentum, further impacting the score. Positive corporate events provide some support but are insufficient to offset the financial challenges.

To see Spark’s full report on AWHL stock, click here.

More about Aspira Women’s Health

Aspira Women’s Health Inc. operates in the women’s health diagnostics industry, providing specialized reference laboratory testing services focused on gynecologic oncology risk assessment. Its key products include the Ova1Plus (Ova1 and Overa) and OvaWatch tests, which are used for clinical decision support in evaluating ovarian masses and assessing ovarian cancer risk.

Average Trading Volume: 73,275

Technical Sentiment Signal: Sell

Current Market Cap: $12.95M

For a thorough assessment of AWHL stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1